Reactive oxygen and nitrogen species: Weapons of neuronal destruction

Oxidative Stress and Age-Related Neurodegeneration

Volumn , Issue , 2005, Pages 107-120

  Mazzulli, Joseph R ^a   Lind, Summer ^a   Ischiropoulos, Harry ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84939890786     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (79)

1. Keller, J.N., Kindy, M.S., Holtsberg, F.W., St. Clair, D.K., Yen, H.C., Germeyer, A., Steiner, S.M., Bruce-Keller, A.J., Hutchins, J.B., and Mattson, M.P. (1998) Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J. Neurosci., 18:687-697.
2. Lebovitz, R.M., Zhang, H., Vogel, H., Cartwright, J. Jr., Dionne, L., Lu, N., Huang, S., and Matzuk, M.M. (1996) Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-difient mice. Proc. Natl. Acad. Sci. USA, 93:9782-9787.
3. Melov, S., Schneider, J.A., Day, B.J., Hinerfeld, D., Coskun, P., Mirra, S.S., Crapo, J.D., and Wallace, D.C. (1998) A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase. Nat. Genet, 18:159-163.
4. Kinouchi, H., Epstein, C.J., Mizui, T., Carlson, E., Chen, S.F., Chan, P.H. (1991) Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase. Proc. Natl. Acad. Sci. USA, 88:11158-11162.
5. Troy, C.M., Derossi, D., Prochiantz, A., Greene, L.A., and Shelanski, M.L. (1996) Downregulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway. J. Neurosci., 16:253-261.
6. Shimizu, K., Rajapakse, N., Horiguchi, T., Payne, R.M., and Busija, D.W. (2003a) Neuroprotection against hypoxia-ischemia in neonatal rat brain by novel superoxide dismutase mimetics. Neurosci. Lett, 346:41-44.
7. Shimizu, K., Rajapakse, N., Horiguchi T., Payne, R.M., and Busija, D.W. (2003b) Protective effect of a new nonpeptidyl mimetic of SOD, M40401, against focal cerebral ischemia in the rat. Brain Res., 963:8-14.
8. Lee, S., Suh, S., and Kim, S. (2000) Protective effects of the green tea polyphenol (-)-epigallacatechin gallate against hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci. Lett, 287:191-194.
9. Mandel, S., Weinreb, O., Amit, T., and Youdim, M.B. (2004) Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gal-late: implications for neurodegenerative diseases. J. Neurochem, 88:1555-1569.
10. Conte, V., Uryu, K., Fujimoto, S., Yao, Y., Rockach, J., Longhi, L., Trojanowski, J.Q., Lee, V.M., McIntosh, T.K., and Pratico, D. (2004) Vitamin E reduces amyloidosis and improves congnitive function in Tg2576 mice following repetitive concussive brain injury. J. Neurochem, 90:758-764.
11. Dawson, V.L., Kizushi, V.M., Huang, P.L., Snyder, S.H., and Dawson, T.M. (1996) Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-deficient mice. J. Neurosci., 16:2479-2487.
12. Huang, Z., Huang, P.L., Panahian, N., Dalkara, T., Fishman, M.C., and Moskowitz, M.A. (1994) Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science, 265:1883-1885.
13. Eliasson, M.J., Huang, Z., Ferrante, R.J., Sasamata, M., Molliver, M.E., Snyder, S.H., and Moskowitz, M.A. (1999) Neuronal nitric oxide synthase activation and peroxynitrite formation in ischemic stroke linked to neural damage. J. Neurosci., 19:5910-5918.
14. Uryu, K., Giasson, B.I., Longhi, L., Martinez, D., Murray, I., Conte, V., Nakamura, M., Saatman, K., Talbot, K., Horiguchi, T., McIntosh T., Lee, V.M., and Trojanowski, J.Q. (2004) Age-dependent synuclein pathology following traumatic brain injury in mice. Exp. Neurol., 184:214-224.
15. Zabar, Y., and Kawas, C.H. (2000) Epidmiology and clinical genetics of Alzheimer’s disease. In: Clark, C.M., and Trojanowski, J.Q., eds. Neurodegenerative Dementias. New York: McGraw-Hill, pp. 79-94.
16. Aksenov, M.Y., Aksenova, M.V., Butterfield, D.A., Geddes, J.W., and Markesbery, W.R. (2001). Protein oxidation in Alzheimer’s disease. Neuroscience, 103:373-383.
17. Smith, M.A., Taneda, S., Richey, P.L., Miyata, S., Yan, S.D., Stern, D., Sayre, L.M., Monnier V.M., Perry, G. (1994) Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. USA., 91:5710-5714.
18. Ledesma, M.D., Bonay, P., Colaco, C., and Avila, J. (1994) Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem., 269:21614-21619.
19. Ledesma, M.D., Bonay, P., and Avila, J. (1995). Tau protein from Alzheimer’s disease patients is glycated at its tubulin-binding domain. J. Neurochem, 65:1658-1664.
20. Lovell, M.A., Ehmann, W.D., Mattson, M.P., and Markesbery, W.R. (1997) Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer’s disease. Neurobiol. Aging, 18:457-461.
21. Montine, K.S., Olson, S.J., Amarnath, V., Whetsell, W.O., Jr., Graham, D.G., and Montine, T.J. (1997) Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer’s disease is associated with inheritance of APOE4. Am. J. Pathol, 150:437-443.
22. Ando, Y., Brannstrom, T., Uchida, K., Nyhlin, N., Nasman, B., Suhr, O., Yamashita, T., Olsson, T., El Salhy, M., Uchino, M., and Ando, M. (1998). Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J. Neurol. Sci, 156:172-176.
23. Perez, M., Cuadros, R., Smith, M.A., Perry, G., and Avila, J. (2000). Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4-hydroxy-2-nonenal. FEBS Lett., 486:270-274.
24. Roberts, L.J. And Morrow, J.D. (1994) Isoprostanes. Novel markers of endogenous lipid peroxidation and potential mediators of oxidant injury. Ann. NY Acad. Sci., 744: 237-242.
25. Pratico, D., Lee, V. M., Trojanowski, J.Q., Rokach, J., and Fitzgerald, G.A. (1998) Increased F2-isoprostanes in Alzheimer’s disease: evidence for enhanced lipid peroxidation in vivo. FASEB J, 12:1777-1783.
26. Pratico, D., Uryu, K., Leight, S., Trojanowski, J.Q., and Lee, V.M. (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci., 21:4183-4187.
27. Hensley, K., Maidt, M.L., Yu, Z., Sang, H., Markesbery, W.R., and Floyd, R.A. (1998). Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J. Neurosci., 18:8126-8132.
28. Smith, M.A., Richey Harris, P.L., Sayre, L.M., Beckman, J.S., and Perry, G. (1997). Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J. Neurosci., 17:2653-2657.
29. Horiguchi, T., Uryu, K., Giasson, B.I., Ischiropoulos, H., Lightfoot, R., Bellmann, C., Richter-Landsberg, C., Lee, V.M., and Trojanowski, J.Q. (2003). Nitration of tau protein is linked to neurodegeneration in tauopathies. Am. J. Pathol., 163:1021-1031.
30. Landino, L.M., Skreslet, T.E., and Alston, J.A. (2004) Cysteine oxidation of tau and microtubule-associated protein-2 by peroxynitrite: modulation of microtubule assembly kinetics by the thioredoxin reductase system. J. Biol. Chem., 279:35101-35105.
31. Cherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, W.D., McLean, C.A., Barnham, K.J., Volitakis, I., Fraser, F.W., Kim, Y., Huang, X., Goldstein, L.E., Moir, R.D., Lim, J.T., Beyreuther, K., Zheng, H., Tanzi, R.E., Masters, C.L., and Bush A.I. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron, 30:665-676.
32. Huang, X., Cuajungco, M.P., Atwood, C.S., Hartshorn, M.A., Tyndall, J.D., Hanson, G.R., Stokes, K.C., Leopold, M., Multhaup, G., Goldstein, L.E., Scarpa, R.C., Saunders, A.J., Lim, J., Moir, R.D., Glabe, C., Bowden, E.F., Masters, C.L., Fairlie, D.P., Tanzi, R.E., and Bush, A.I. (1999) Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem, 274:37111-37116.
33. Yokota, T., Igarashi, K., Uchihara, T., Jishage, K., Tomita, H., Inaba, A., Li, Y., Arita, M., Suzuki, H., Mizusawa, H., and Arai, H. (2001) Delayed-onset ataxia in mice lacking alpha-tocopherol transfer protein: model for neuronal degeneration caused by chronic oxidative stress. Proc. Natl. Acad. Sci., 98:15185-15190.
34. Sano M., Ernesto, C., Thomas, R.G., Klauber M.R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C.W., Pfeiffer, E., Schneider, L.S., and Thal, L.J. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N. Engl. J. Med, 336:1216-1222.
35. Nakashima, H., Ishihara, T., Yokota, O., Terada, S., Trojanowski, J.Q., Lee, V.M., and Kuroda, S. (2004) Effects of alpha-tocopherol on an animal model of tauopathies. Free Radic. Biol. Med., 37:176-186.
36. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature, 388:839-840.
37. Giasson, B.I., Galvin, J.E., Lee, V.M., and Trojanowski, J.Q. (2000a) The cellular and molecular pathology of Parkinson’s disease. In: Clark, C.M., and Trojanowski, J.Q., eds. Neurodegenerative Dementias. New York: McGraw-Hill, pp. 219-228.
38. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di Iorio, G., Golbe, L.I., and Nussbaum, R.L. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science, 276:2045-2047.
39. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J.T., Schols, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet, 18:106-108.
40. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer, D., and Rosenthal, A. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25:239-252.
41. Cabin, D.E., Shimazu, K., Murphy, D., Cole, N.B., Gottschalk, W., McIlwain, K.L., Orrison, B., Chen, A., Ellis, C.E., Paylor, R., Lu, B., and Nussbaum, R.L. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci., 22: 8797-8807.
42. Ahn, B.H., Rhim, H., Kim, S.Y., Sung, Y.M., Lee, M.Y., Choi, J.Y., Wolozin, B., Chang, J.S., Lee, Y.H., Kwon, T.K., Chung, K.C., Yoon, S.H., Hahn, S.J., Kim, M.S., Jo, Y.H., and Min do, S. (2002) alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. J. Biol. Chem, 277:12334-12342.
43. Perez, R.G., Waymire, J.C., Lin, E., Liu, J.J., Guo, F., and Zigmond, M.J. (2002) A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci., 22:3090-3099.
44. Wersinger, C. And Sidhu, A. (2003) Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci. Lett, 340:189-192.
45. Ostrerova, N., Petrucelli, L., Farrer, M., Mehta, N., Choi, P., Hardy, J., and Wolozin, B. (1999) alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci., 19:5782-5791.
46. Souza, J.M., Giasson, B.I., Lee, V.M., and Ischiropoulos, H. (2000a) Chaperonelike activity of synucleins. FEBS Lett., 474:116-119.
47. Ostrerova-Golts, N., Petrucelli, L., Hardy, J., Lee, J.M., Farer, M., and Wolozin, B. (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci., 20:6048-6054.
48. Paik, S.R., Shin, H.J., and Lee, J.H. (2000) Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. Arch. Biochem. Biophys., 378:269-277.
49. Krishnan, S., Chi, E.Y., Wood, S.J., Kendrick, B.S., Li, C., Garzon-Rodriguez, W., Wypych, J., Randolph, T.W., Narhi, L.O., Biere, A.L., Citron, M., and Carpenter, J.F. (2003). Oxidative dimer formation is the critical rate-limiting step for Parkinson’s Disease alpha-Synuclein fibrillogenesis. Biochemistry, 42:829-837.
50. Conway, K.A., Rochet, J.C., Bieganski, R.M., and Lansbury, P.T. (2001). Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science, 294:1346-1349.
51. Lashuel, H.A., Hartley, D., Petre, B.M., Walz, T., and Lansbury, P.T. (2002). Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature, 418:291.
52. Volles, M.J., Lee, S.J., Rochet, J.C., Shtilerman, M.D., Ding, T.T., Kessler, J.C., and Lansbury, P.T. (2001) Vesicle permeabilization by protofibrillar alpha-synu-clein: implications for the pathogenesis and treatment of Parkinson’s disease. Biochemistry, 40:7812-7819.
53. Giasson, B.I., Duda, J.E., Murray, I.V., Chen, Q., Souza, J.M., Hurtig, H.I., Ischiropoulos, H., Trojanowski, J.Q., and Lee, V.M.-Y. (2000b). Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucle-inopathy lesions. Science, 290:985-989.
54. Souza, J.M., Giasson, B.I., Chen, Q., Lee, V.M.-Y., and Ischiropoulos, H. (2000b). Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem, 275:18344-18349.
55. Norris, E.H., Giasson, B.I., Ischiropoulos, H., and Lee, V.M.-Y. (2003). Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J. Biol. Chem, 278: 27230-27240.
56. Hodara, R., Norris, E.H., Giasson, B.I., Mishizen-Eberz, A.J., Lynch, D.R., Lee, V.M., and Ischiropoulos, H. (2004) Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J. Biol. Chem, 279:47746-47753.
57. Manning-Bog, A.B., McCormack, A.L., Li, J., Uversky, V.N., Fink, A.L., and DiMonte, D.A. (2002) The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem., 277:1641-1644.
58. Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V., and Greenamyre, J.T. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci., 3:1301-1306.
59. Sherer, T.B., Betarbet, R., Stout, A.K., Lund, S., Baptista, M., Panov, A.V., Cookson, M.R., and Greenamyre, J.T. (2002). An in vitro model of Parkinson’s disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci., 22:7006-7015.
60. Lee, H.J., Shin, S.Y., Choi, C., Lee, Y.H., and Lee, S.J. (2002) Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem., 277:5411-5417.
61. Vila, M. And Przedborski, S. (2003) Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci., 4:365-375.
62. Forno, L.S., Langston, J.W., DeLanney, L.E., and Irwin, I. (1988) An electron microscopic study of MPTP-induced inclusion bodies in an old monkey. Brain Res., 448:150-157.
63. Kowall, N.W., Hantraye, P., Brouillet, E., Beal, M.F., McKee, A.C., and Ferrante, R.J. (2000) MPTP induces alpha-synuclein aggregation in the substatia nigra of baboons. Neuroreport, 11:211-213.
64. Przedborski, S., Jackson-Lewis, V., Yokoyama, R., Shibata, T., Dawson, V.L., and Dawson, T.M. (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. USA, 93:4565-4571.
65. Liberatore, G.T., Jackson-Lewis, V., Vukosavic, S., Mandir, A.S., Vila, M., McAuliffe, W.G., Dawson, V.L., Dawson, T.M., Przedborski, S. (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med., 5:1403-1409.
66. Schulz, J.B., Matthews, R.T., Muqit, M.M., Browne, S.E., and Beal, M.F. (1995) Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem, 64:936-939.
67. Kuhn, D.M., Aretha, C.W., and Geddes, T.J. (1999) Peroxynitrite inactivation of tyrosine hydroxylase: mediation by sulfhydryl oxidation, not tyrosine nitration. J. Neurosci., 19:10289-10294.
68. Kuhn, D.M., Sadidi, M., Liu, X., Kreipke, C., Geddes, T., Borges, C., and Watson, J.T. (2002) Peroxynitrite-induced nitration of tyrosine hydroxylase: identification of tyrosines 423, 428, and 432 as sites of modification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry and tyrosine-scanning mutagenesis. J. Biol. Chem., 277:14336-14342.
69. Ara, J., Przedborski, S., Naini, A.B., Jackson-Lewis, V., Trifiletti, R.R., Horwitz, J., and Ischiropoulos, H. (1998) Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropy-ridine (MPTP). Proc. Natl. Acad. Sci. USA, 95:7659-7663.
70. Blanchard-Fillion, B., Souza, J.M., Friel, T., Jiang, G.C., Vrana, K., Sharov, V., Barron, L., Schoneich, C., Quijano, C., Alvarez, B., Radi, R., Przedborski, S., Fernando, G.S., Horwitz, J., and Ischiropoulos, H. (2001) Nitration and inactivation of tyrosine hydroxylase by peroxynitrite. J. Biol. Chem, 276:46017-46023.
71. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M.R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., and Gwinn-Hardy, K. (2003) alpha-Synuclein locus triplication causes Parkinson’s disease. Science, 302:841.
72. Hsu, L.J., Sagara, Y., Arroyo, A., Rockenstein, E., Sisk, A., Mallory, M., Wong, J., Takenouchi, T., Hashimoto, M., and Masliah, E. (2000) alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol., 157:401-410.
73. Valente, E.M., Abou-Sleiman, P.M., Caputo, V., Muqit, M.M., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A.R., Healy, D.G., Albanese, A., Nussbaum, R., Gonzalez-Maldonado, R., Deller, T., Salvi, S., Cortelli, P., Gilks, W.P., Latchman, D.S., Harvey, R.J., Dallapiccola, B., Auburger, G., and Wood, N.W. (2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science, 304:1158-1160.
74. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., and Shimizu, N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392:605-608.
75. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, and Polymeropoulos MH. (1998) The ubiquitin pathway in Parkinson’s disease. Nature, 395: 451-452.
76. Palacino, J.J., Sagi, D., Goldberg, M.S., Krauss, S., Motz, C., Wacker, M., Klose, J., and Shen, J. (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem., 279:18614-18622.
77. Bonifati, V., Rizzu, P., van Baren, M.J., Schaap, O., Breedveld, G.J., Krieger, E., Dekker, M.C., Squitieri, F., Ibanez, P., Joosse, M., van Dongen, J.W., Vanacore, N., van Swieten, J.C., Brice, A., Meco, G., van Duijn, C.M., Oostra, B.A., and Heutink, P. (2002) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 299:256-259.
78. Taira, T., Saito, Y., Niki, T., Iguchi-Ariga, S.M., Takahashi, K., and Ariga, H. (2004) DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep., 5:213-218.
79. Moore, D.J., Zhang, L., Dawson, T.M., and Dawson, V.L. (2003) A missense mutation (L166P) in DJ-1, linked to familial Parkinson’s disease, confers reduced protein stability and impairs homo-oligomerization. J. Neurochem., 87:1558-1567.